UTHealth Houston researchers found 11% lower odds of major heart complications, but the real gap works out to about one fewer event per 1,000 patients.
Recap by typeshit. Full story at Yahoo.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
Mounjaro became India's top-selling drug in 2025, and a Scroll investigation reports that pharmacies are handing it out without the prescription it requires.
Traders Union looks at whether Novo Nordisk shares can hold their gains, pointing to the Wegovy pill approval and recent trial data.
Loading…